このアイテムのアクセス数: 362

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
j.stemcr.2017.07.020.pdf2.92 MBAdobe PDF見る/開く
完全メタデータレコード
DCフィールド言語
dc.contributor.authorIchise, Hiroshien
dc.contributor.authorNagano, Seijien
dc.contributor.authorMaeda, Takuyaen
dc.contributor.authorMiyazaki, Masakien
dc.contributor.authorMiyazaki, Yukien
dc.contributor.authorKojima, Hirotoen
dc.contributor.authorYawata, Nobuyoen
dc.contributor.authorYawata, Makotoen
dc.contributor.authorTanaka, Hidenorien
dc.contributor.authorSaji, Hirohen
dc.contributor.authorMasuda, Kyokoen
dc.contributor.authorKawamoto, Hiroshien
dc.contributor.alternative一瀬, 大志ja
dc.contributor.alternative永野, 誠治ja
dc.contributor.alternative前田, 卓也ja
dc.contributor.alternative宮崎, 正輝ja
dc.contributor.alternative宮崎, 有紀ja
dc.contributor.alternative小島, 裕人ja
dc.contributor.alternative八幡, 信代ja
dc.contributor.alternative八幡, 真人ja
dc.contributor.alternative田中, 秀則ja
dc.contributor.alternative佐治, 博夫ja
dc.contributor.alternative増田, 喬子ja
dc.contributor.alternative河本, 宏ja
dc.contributor.transcriptionイチセ, ヒロシja-Kana
dc.contributor.transcriptionナガノ, セイジja-Kana
dc.contributor.transcriptionマエダ, タクヤja-Kana
dc.contributor.transcriptionミヤザキ, マサキja-Kana
dc.contributor.transcriptionミヤザキ, ユキja-Kana
dc.contributor.transcriptionコジマ, ヒロトja-Kana
dc.contributor.transcriptionヤワタ, ノブヨja-Kana
dc.contributor.transcriptionヤワタ, マコトja-Kana
dc.contributor.transcriptionタナカ, ヒデノリja-Kana
dc.contributor.transcriptionサジ, ヒロオja-Kana
dc.contributor.transcriptionマスダ, キョウコja-Kana
dc.contributor.transcriptionカワモト, ヒロシja-Kana
dc.date.accessioned2017-09-01T02:29:23Z-
dc.date.available2017-09-01T02:29:23Z-
dc.date.issued2017-09-12-
dc.identifier.issn2213-6711-
dc.identifier.urihttp://hdl.handle.net/2433/226956-
dc.descriptioniPS細胞から再生した細胞への免疫反応とその制御法 --今後のストック事業で起こりうる拒絶反応への対処法を提案--. 京都大学プレスリリース. 2017-09-01.ja
dc.description.abstractHLA haplotype-homozygous (HLA-homo) induced pluripotent stem cells (iPSCs) are being prepared to be used for allogeneic transplantation of regenerated tissue into recipients carrying an identical haplotype in one of the alleles (HLA-hetero). However, it remains unaddressed whether natural killer (NK) cells respond to these regenerated cells. HLA-C allotypes, known to serve as major ligands for inhibitory receptors of NK cells, can be classified into group 1 (C1) and group 2 (C2), based on their binding specificities. We found that the T cells and vascular endothelial cells regenerated from HLA-homo-C1/C1 iPSCs were killed by specific NK cell subsets from a putative HLA-hetero-C1/C2 recipient. Such cytotoxicity was canceled when target cells were regenerated from iPSCs transduced with the C2 gene identical to the recipient. These results clarify that NK cells can kill regenerated cells by sensing the lack of HLA-C expression and further provide the basis for an approach to prevent such NK cell-mediated rejection responses.en
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherElsevier BVen
dc.rights© 2017 The Authors. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).en
dc.subjectiPSCsen
dc.subjectNK cellsen
dc.subjectKIRen
dc.subjectKIR liganden
dc.subjectHLA-Cen
dc.subjecttransplantationen
dc.subjectregenerationen
dc.subjectvascular endothelial cellsen
dc.subjectHLA haplotype-homozygoteen
dc.subjectmissing-self recognitionen
dc.titleNK Cell Alloreactivity against KIR-Ligand-Mismatched HLA-Haploidentical Tissue Derived from HLA Haplotype-Homozygous iPSCsen
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.jtitleStem Cell Reportsen
dc.identifier.volume9-
dc.identifier.issue3-
dc.identifier.spage853-
dc.identifier.epage867-
dc.relation.doi10.1016/j.stemcr.2017.07.020-
dc.textversionpublisher-
dc.identifier.pmid28867344-
dc.relation.urlhttps://www.kyoto-u.ac.jp/ja/research-news/2017-09-01-0-
dcterms.accessRightsopen access-
dc.identifier.eissn2213-6711-
出現コレクション:学術雑誌掲載論文等

アイテムの簡略レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。